


Antifibrotics up outcomes after ahmed glaucoma valve implant

August 11 2016



(HealthDay)—Mitomycin C (MMC) and 5-flurouracil (5-FU) improve



outcomes following Ahmed glaucoma valve (AGV) implantation, according to a study published online Aug. 4 in *Clinical & Experimental Ophthalmology*.

Qi N. Cui, M.D., Ph.D., from the University of California in San Francisco, and colleagues examined the effect of MMC and 5-FU on treatment outcomes for 50 patients who received AGV implantation. Patients received intraoperative MMC followed by postoperative injections of MMC and/or 5-FU (+INJECTION) group (26 patients/eyes) or not (–INJECTION; 24 patients/eyes).

The researchers observed higher treatment success in the +INJECTION group versus the –INJECTION group (86 versus 58 percent; P = 0.04). At one, three, six, and 12 months, intraocular pressure was lower in the +INJECTION group versus the –INJECTION group. In the +INJECTION group, hypertensive phase (HP) occurred less often (3.8 percent, compared to 54 percent in the –INJECTION group; P = 0.021). At one, three, six, and 12 months, fewer medications were required by the +INJECTION group. Comparable complication rates were seen between the +INJECTION and –INJECTION groups (46.2 and 54.2 percent, respectively; P = 0.63).

"Adjuvant treatment with antifibrotics following AGV implantation decreased the HP and improved surgical outcomes without impacting complication rates at one year," the authors write. "This study postulates a role for antifibrotics in the postoperative management of AGV implantation."

More information: Abstract

Full Text (subscription or payment may be required)

Copyright © 2016 HealthDay. All rights reserved.



Citation: Antifibrotics up outcomes after ahmed glaucoma valve implant (2016, August 11) retrieved 10 April 2024 from

https://medicalxpress.com/news/2016-08-antifibrotics-outcomes-ahmed-glaucoma-valve.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.